Smith Ian A R, McLeod Nicholas, Rashid Prem
Liverpool Hospital, Sydney, and Faculty of Medicine, University of Western Sydney and University of New South Wales, Australia.
Aust Fam Physician. 2010 May;39(5):301-5.
Erectile dysfunction (ED) is a common clinical problem managed in the general practice setting. While the majority of men will find phosphodiesterase-5 (PDE-5) inhibitors effective, there is a subgroup of men who require second and third line therapies.
This article provides an overview of ED and its management with particular focus on the group of patients in whom oral agents fail.
Erectile dysfunction is a multifactorial condition that affects approximately 40% of Australian men. The incidence of ED is age related however, it shares common risk factors with cardiovascular disease and metabolic disorders. The management of ED should begin with an assessment of cardiovascular risk factors, advice on lifestyle modification, and a trial of PDE-5 inhibitors. Second line therapies include intracavernosal injections and vacuum erection devices, while third line therapy entails penile implants. Factors that influence treatment success include partner inclusion, good patient selection, as well as ongoing support and education.
勃起功能障碍(ED)是普通门诊中常见的临床问题。虽然大多数男性会发现磷酸二酯酶-5(PDE-5)抑制剂有效,但有一部分男性需要二线和三线治疗。
本文概述勃起功能障碍及其治疗,特别关注口服药物治疗失败的患者群体。
勃起功能障碍是一种多因素疾病,影响约40%的澳大利亚男性。勃起功能障碍的发病率与年龄有关,然而,它与心血管疾病和代谢紊乱有共同的风险因素。勃起功能障碍的治疗应从评估心血管风险因素、提供生活方式改变建议以及试用PDE-5抑制剂开始。二线治疗包括海绵体内注射和真空勃起装置,而三线治疗需要阴茎植入。影响治疗成功的因素包括伴侣参与、良好的患者选择以及持续的支持和教育。